The American Journal of Psychiatry has once again received recognition from New England Journal of M...

Long-term treatment with valbenazine for tardive dyskinesia (TD) appears to be safe and well-tolerat...

Teva Pharmaceuticals Ltd. on Wednesday announced that the Food and Drug Administration has approved ...

The Food and Drug Administration on Tuesday announced it approved Ingrezza (valbenazine) capsules to...

Once-daily treatment with valbenazine (NBI-98854), a highly selective vesicular monoamine transport ...